Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Dev Biol. 2011 Nov 6;362(1):24–41. doi: 10.1016/j.ydbio.2011.10.033

Figure 11.

Figure 11

VEGFA and VEGFC are sufficient to induce Notch-dependent activation of lymphangiogenic markers in fetal lung mesenchyme. A) Diagram outlining the experimental protocol. Lung mesenchyme was isolated from E12.5 mice on d0, treated as indicated and analyzed at d3. Scale bar = 100μm. B) qPCR analysis of fetal lung mesenchyme on d3 following treatment with VEGFA-165, VEGFC and/or treatment with the Notch pathway inhibitor DAPT. Note that both VEGFA and VEGFC recombinant proteins were sufficient to induce Foxc2, Hey1, Heyl and Sox18 and that this induction was inhibited by co-treatment with the Notch inhibitor DAPT. Data are compiled from 3 separate experiments, with 3 samples per group in each experiment. *p<0.05 vs. untreated mesenchyme control. C) Model of epithelial HIF1a induction of VEGFA and VEGFC and the downstream activation of lymphangiogenic markers on endothelial cell precursors in the fetal lung mesenchyme.